Long term cancer-specific anxiety in men undergoing active surveillance for prostate cancer: findings from a large prospective cohort
Active surveillance is the preferred management of men with low-risk prostate cancer. Cancer-specific anxiety during active surveillance remains understudied. We sought to report long-term anxiety for men on active surveillance to determine if interventions need to be tailored to improve adherence.
Prostate cancer in Australia statistics
Estimated number of new cases of prostate cancer diagnosed in 2019 – 19,508 males
Estimated % of all new male cancer cases diagnosed in 2019 – 25%
Estimated number of deaths from prostate cancer in 2019 – 3,306 males
Estimated % of all male deaths from cancer in 2019 – 12%
5-year cancer control comparable for focal therapy, RP
A multicenter study in the United Kingdom found 5-year prostate cancer control rates following treatment with focal therapy are similar to those of patients who have undergone radical prostatectomy, even when accounting for variation in tumor location, size, and risk.
New and Established Technology in Focal Ablation of the Prostate:
A Systematic Review
Focal therapy has been evaluated using seven sources of energy in single-arm retrospective and prospective development studies up to Stage 2b. Focal therapy seems to have a minor impact on quality of life and genito-urinary function. Oncological effectiveness is yet to be defined against standard of care.
UC Cancer Institute treats first prostate cancer patient with focal therapy
CINCINNATI (WKRC) – The first patient in the Tri-State receives a breakthrough therapy to treat prostate cancer.
Focal Therapy, AuroLase, Shows Good Safety and Potential Effectiveness in Pilot Clinical Trial
Nanospectra Biosciences’ AuroLase Therapy, a focal therapy for prostate cancer that uses gold-silica nanoparticles, showed a good safety profile and evidence of successfully eliminating the cancer in a pilot clinical trial. Results were published in the journal PNAS.